文献速递病毒性肝炎

替诺福韦酯治疗慢性乙型肝炎的肝硬化和非肝硬化患者肝细胞癌发生率降低:一项倾向评分匹配研究

Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
PubMed 文献 · J Infect Dis · 2019-01-01

这项回顾性队列研究纳入6914例慢性HBV单一感染且无移植史的成人,经倾向评分匹配后各591例接受或未接受替诺福韦酯(TDF)治疗。匹配后未治疗组8年肝细胞癌累积发生率显著更高(20.13% vs 4.69%;P < .0001)。调整多因素后,TDF与肝硬化患者肝细胞癌风险降低77%相关(aHR,0.23;95%CI,.56-.92),非肝硬化患者降低73%(aHR,0.27;95%CI,.07-.98)。

要点

  • 匹配后未治疗组8年肝细胞癌累积发生率为20.13%,TDF组为4.69%(P < .0001)。
  • 肝硬化是肝细胞癌的显著预测因素(aHR,5.36;95%CI,2.73-10.51;P < .001)。
  • TDF与肝硬化患者肝细胞癌风险降低77%相关(aHR,0.23;95%CI,.56-.92)。

核心结论

  • 在肝硬化和非肝硬化亚洲慢性乙型肝炎患者中,TDF治疗与8年肝细胞癌累积发生率降低显著相关。

研究设计与样本

  • 回顾性队列研究,纳入6914例慢性HBV单一感染且无移植史的成人,来自6个美国转诊、社区医疗中心和一个台湾社区队列。
  • 774例接受TDF治疗,6140例未治疗;对年龄、性别、HBeAg状态、HBV DNA水平、ALT水平、基线肝硬化状态和随访时间进行倾向评分匹配后,各591例。

主要发现

  • 匹配后未治疗组8年肝细胞癌累积发生率为20.13%,TDF组为4.69%(P < .0001)。
  • 肝硬化是肝细胞癌的显著预测因素(aHR,5.36;95%CI,2.73-10.51;P < .001)。
  • 调整年龄、性别、HBV DNA水平、ALT水平和研究中心后,肝硬化患者中TDF与肝细胞癌风险降低77%相关(aHR,0.23;95%CI,.56-.92)。
  • 非肝硬化患者中TDF与肝细胞癌风险降低73%相关(aHR,0.27;95%CI,.07-.98)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of newer oral anti-hepatitis B virus (HBV) medication, tenofovir disoproxil (TDF), on liver-related outcomes among Asians is limited. We examined the effect of TDF on the incidence of hepatocellular carcinoma (HCC) in an Asian population with chronic hepatitis B (CHB). METHODS: This was a retrospective cohort study of 6914 adults with chronic HBV monoinfection and no history of transplantation who were recruited from 6 US referral, community medical centers and a community based Taiwan cohort for a total of 774 patients who received TDF and 6140 who were not treated. Propensity score matching (PSM) for age, sex, HBV e antigen status, HBV DNA level, alanine aminotransferase (ALT) level, baseline cirrhosis status, and follow-up time was performed to balance the groups, resulting in 591 treated individuals and 591 untreated individuals. Kaplan-Meier analysis was used to estimate the cumulative risk of HCC. Cox proportional hazards models were run to estimate the HCC risk between groups. RESULTS: The 8-year cumulative HCC incidence was significantly higher in the PSM untreated group (20.13% vs 4.69%; P < .0001). Cirrhosis was a significant predictor for HCC (adjusted hazard ratio [aHR], 5.36; 95% confidence interval [CI], 2.73-10.51; P < .001). On multivariate analysis adjusted for age, sex, HBV DNA level, ALT level, and study site, TDF was associated with a 77% reduction in the risk of HCC (aHR, 0.23; 95% CI, .56-.92) in patients with cirrhosis and a 73% reduction (aHR, 0.27; 95% CI, .07-.98) in patients without cirrhosis. CONCLUSIONS: Among cirrhotic and noncirrhotic Asian patients with CHB, TDF therapy was significantly associated with a reduction in the 8-year HCC cumulative incidence rate.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Nguyen MH, Yang HI, Le A, et al. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study. J Infect Dis. 2019. PMID: 29982737. doi:10.1093/infdis/jiy391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。